187 related articles for article (PubMed ID: 14730454)
21. Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.
Marucci G; Di Oto E; Farnedi A; Panzacchi R; Ligorio C; Foschini MP
Hum Pathol; 2012 Mar; 43(3):374-80. PubMed ID: 21835431
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
23. OLIG-1 and 2 gene expression and oligodendroglial tumours.
Hoang-Xuan K; Aguirre-Cruz L; Mokhtari K; Marie Y; Sanson M
Neuropathol Appl Neurobiol; 2002 Apr; 28(2):89-94. PubMed ID: 11972795
[TBL] [Abstract][Full Text] [Related]
24. Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.
Suzuki A; Nobusawa S; Natsume A; Suzuki H; Kim YH; Yokoo H; Nagaishi M; Ikota H; Nakazawa T; Wakabayashi T; Ohgaki H; Nakazato Y
J Neurooncol; 2014 Nov; 120(2):283-91. PubMed ID: 25085214
[TBL] [Abstract][Full Text] [Related]
25. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
26. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
[TBL] [Abstract][Full Text] [Related]
27. Altered expression of immune defense genes in pilocytic astrocytomas.
Huang H; Hara A; Homma T; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 2005 Oct; 64(10):891-901. PubMed ID: 16215461
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical and ultrastructural characterization of brain tumors in S100beta-v-erbB transgenic rats.
Yokoo H; Tanaka Y; Nobusawa S; Nakazato Y; Ohgaki H
Neuropathology; 2008 Dec; 28(6):591-8. PubMed ID: 18498286
[TBL] [Abstract][Full Text] [Related]
29. Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
Ishizawa K; Komori T; Shimada S; Hirose T
Clin Neuropathol; 2008; 27(3):118-28. PubMed ID: 18552083
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas.
Soichi O; Masanori N; Hideo T; Kazunori A; Nobuya I; Jun-ichi K
Neurosurgery; 2007 Apr; 60(4):707-14; discussion 714. PubMed ID: 17415208
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
[TBL] [Abstract][Full Text] [Related]
32. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.
Smith JS; Wang XY; Qian J; Hosek SM; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2000 Jun; 59(6):495-503. PubMed ID: 10850862
[TBL] [Abstract][Full Text] [Related]
33. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
34. [Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis].
Kondo T
Brain Nerve; 2009 Jul; 61(7):741-51. PubMed ID: 19618851
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
Tews B; Felsberg J; Hartmann C; Kunitz A; Hahn M; Toedt G; Neben K; Hummerich L; von Deimling A; Reifenberger G; Lichter P
Int J Cancer; 2006 Aug; 119(4):792-800. PubMed ID: 16550607
[TBL] [Abstract][Full Text] [Related]
36. Loss of 14q chromosome in oligodendroglial and astrocytic tumors.
Dichamp C; Taillibert S; Aguirre-Cruz L; Lejeune J; Marie Y; Kujas M; Delattre JY; Hoang-Xuan K; Sanson M
J Neurooncol; 2004 May; 67(3):281-5. PubMed ID: 15164983
[TBL] [Abstract][Full Text] [Related]
37. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms.
Otero JJ; Rowitch D; Vandenberg S
J Neurooncol; 2011 Sep; 104(2):423-38. PubMed ID: 21193945
[TBL] [Abstract][Full Text] [Related]
38. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
39. Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas.
Neder L; Marie SK; Carlotti CG; Gabbai AA; Rosemberg S; Malheiros SM; Siqueira RP; Oba-Shinjo SM; Uno M; Aguiar PH; Miura F; Chammas R; Colli BO; Silva WA; Zago MA
Brain Pathol; 2004 Oct; 14(4):399-405. PubMed ID: 15605987
[TBL] [Abstract][Full Text] [Related]
40. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas.
von Deimling A; Louis DN; von Ammon K; Petersen I; Wiestler OD; Seizinger BR
Cancer Res; 1992 Aug; 52(15):4277-9. PubMed ID: 1353411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
